JMP Securities analyst Jason Butler initiated Gamida Cell with an Outperform rating and a price target of $16. The analyst cites expected phase 3 results from the company's lead program of omidubicel in stem cell transplants some time in the first half of 2020, which he calls the primary value driver for the stock. Butler assigns a 75% chance of approval for omidubicel with modeled sales of about $580M by 2027. The analyst further points to Gamida Cell's second clinical program, GDA-201, which "leverages natural killer cells" to provide an immunotherapy for cancer.